ASAIO 2015: Sharing our Research and Expanding our Expertise in Mechanical Circulatory Support
August 1, 2015 - Matt Stoll, Product Manager, Neurocritical Care
As part of our ongoing commitment to the field of mechanical circulatory support, Minnetronix recently exhibited at the American Society of Artificial Internal Organs (ASAIO) 61st annual conference. We traveled to sunny Chicago for three days in June to host an exhibit booth, attend the scientific sessions, and engage with experts and clinicians in the space.
My colleagues Lori Lucke and Kellie Ryan presented two posters at the meeting:
- User Studies and the Design of a Completely Implantable VAD System
Download The Poster
- Extending the TET System for Improved Patient Comfort
Download The Poster
This research was well-received and contributed to a healthy debate about percutaneously-powered vs. transcutaneously-powered VADs. In addition, we displayed our TET system at our booth, and it continued to draw enthusiasm from clinicians (most common question: ‘when will it be available?’) and curiosity from technical staff (most common question: ‘can I take a picture?’).
Attendance has been growing at ASAIO with an increase in interest in bioengineering and renal and, of course, a continued strong interest in cardiac topics. This year, in addition to the VAD coordinator session, more than 200 participants attended a day-long series of sessions on ECMO. One highlight for the Minnetronix team was the back-to-back talks by Marc Dickstein, MD and Daniel Burkhoff, MD, PhD. Dr. Dickstein spoke about the physiology of ECMO and modeling it ( www.ecmoed.com is a free resource to learn about it), and Dr. Burkhoff followed up with the cardiovascular physiology of right ventricular heart failure and pulmonary hypertension.
This past April, Minnetronix engineers also journeyed to France for the International Society for Heart & Lung Transplantation (ISHLT) 35th annual meeting. Our participation in these industry conferences underscores our commitment to improving the quality of life for VAD patients through next-generation VAD technology development.